Drugs / EVT 302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00738595 | Aug 2008 → Mar 2009 | — | Evotec Neurosciences GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00622752 | Feb → May 2008 | — | Evotec Neurosciences GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVT 302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00738595 ↗ |
| Action | Inhibit | “a potent and selective inhibitor of Monoamine Oxidase - B” NCT00738595 ↗ |